Recludix Pharma Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a signal transducer and activator of transcription 3 (STAT3) targeting moiety via a linker acting as STAT3 degradation inducers reported to be useful for the treatment of cancer and inflammatory disorders.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS).
A federal jury awarded Insulet Corp. $452 million against Eoflow Co. Ltd., concluding that Eoflow and other defendants stole trade secrets to create the Eopatch, a device with striking similarities to Omnipod, Insulet’s market-dominating tubeless insulin pump.
Several recent Celgene Corp. patents detail the development of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety via a linker.
Work at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. has led to the discovery of new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast cancer and castration-resistant prostate cancer.
A Jiangsu Hengrui Medicine Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. patent describes new fibroblast activation protein-α (FAP-α) inhibitors comprising a chelator and a radiolabeled compound potentially useful for the diagnosis and treatment of cancer.
Glenmark Pharmaceuticals Ltd. has synthesized substituted biphenyl compounds acting as E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.
The Agency for Science Technology & Research (A*STAR) Bioprocessing Technology Institute has patented 3C-like proteinase (3CLpro; Mpro; nsp5) (coronavirus) inhibitors.
RSS
